Chinese Premier Calls for S&T, Policy Support to Boost Biopharmaceuticals

Translation. Region: Russian Federal

Source: People's Republic of China in Russian – People's Republic of China in Russian –

An important disclaimer is at the bottom of this article.

Source: People's Republic of China – State Council News

BEIJING, Aug. 20 (Xinhua) — Chinese Premier Li Qiang on Wednesday called for increasing the supply of high-quality scientific and technological resources and strengthening policy support to promote the upgrading and upgrading of the biopharmaceutical industry.

Li Qiang, also a member of the Standing Committee of the Politburo of the CPC Central Committee, made the remarks during an inspection tour in the Chinese capital Beijing.

During his visit to the Changping Laboratory, Li Qiang called for focusing on the world's leading trends and important areas, achieving significant original results, and cultivating more highly qualified personnel in the field of life sciences, thereby continuously strengthening the foundation for the development of China's biopharmaceutical industry.

After visiting a biotech enterprise and an international innovation center, the Chinese leader stressed the importance of encouraging domestic enterprises to deepen international cooperation, enhance their innovation and competitiveness, and optimize platform construction and operation models.

Li Qiang also attended the seminar, calling for pursuing original innovations and breakthroughs in core technologies in key areas, and paying special attention to the application of artificial intelligence to advance the comprehensive promotion of industrial development.

In addition, the Premier called for more effective management of the use of high-quality innovative drugs and called for promoting the modernization and industrialization of traditional Chinese medicine. –0–

Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.

.